Sign up for our newsletter and get 20% off your first order!

Daily Research Brief

NAD+: Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure.

Nature cancer · 2025

3 minute read1/1/2025animal

Chimeric antigen receptor (CAR) T cell therapy is one of the most promising cancer treatments. However, different hurdles are limiting its application and efficacy. In this context, how aging influences CAR-T cell outcomes is largely unknown.

What the study reported

How to read it carefully

Confirm the complete study design, intervention identity, population or model, outcomes, statistical context, and limitations in the linked source before approval.

Research context only. This brief summarizes a published source and does not establish clinical efficacy, safety, dosing, or suitability for human or veterinary use. Review the original paper before drawing conclusions.
Read the original source · Nature cancer
← Back to the newsletter